最近瘤微环境的进展影响了胃癌中免疫疗法耐药性的进展
Qiuhong Sun1, Shihui Li1, Jing Lou1
1Department of Oncology, Beijing Electric Power Hospital of State Grid Co. of China, Capital Medical University Electric Teaching Hospital, Beijing 100073, China.
Critical reviews in oncology/hematology
|July 6, 2025
概括
胃癌免疫疗法面临着由于耐药性的挑战. 本综述探讨了瘤微环境 (TME) 和代谢重编程如何驱动抗性,为克服这些障碍提供了更好的患者结果的见解.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 胃癌 (GC) 由于晚期诊断和治疗耐药性,给全球健康带来了重大挑战.
- 免疫疗法,特别是免疫检查点抑制剂,为GC提供了希望,但面临着相当大的耐药性.
- 瘤微环境 (TME) 和代谢重编程是影响GC免疫疗法耐药性的关键因素.
研究的目的:
- 阐明TME成分对胃癌免疫疗法耐药性的机制.
- 审查TME因素和代谢重编程对GC免疫疗法耐药性的影响.
- 讨论潜在的策略和未来的研究方向,以克服GC的免疫疗法耐药性.
主要方法:
- 文献综述侧重于TME在GC免疫疗法耐药性中的作用.
- 分析涉及TME内的免疫抑制细胞,纤维细胞,细胞外基质和细胞因子的机制.
- 检查瘤代谢重编程对免疫细胞功能和抗性的影响.
主要成果:
- 关键的TME成分,包括免疫抑制细胞和与癌症相关的纤维细胞,创造了一个免疫抑制的环境,阻碍了免疫疗法的有效性.
- 瘤代谢重编程通过改变免疫细胞活性,进一步加剧免疫抵抗.
- 对这些机制缺乏全面的理解,这突显了当前文献中的差距.
结论:
- 胃癌的TME和代谢重编程是推动胃癌免疫疗法耐药性的关键.
- 针对TME组件和代谢途径提出了潜在的治疗策略.
- 需要进一步的研究来开发全面的方法来克服耐药性并改善GC患者的预后.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.3K
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.1K
相关概念视频
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
01:27Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:30Cancer Vaccines
517
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
517
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K